EVAX Q1 2024 Earnings — Evaxion Biotech A/S Revenue & Financial Results | Market Cap Arena

EVAXEvaxion Biotech A/S

$20M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$51,000

Gross Profit

$51,000100.0% margin

Operating Income

-$4M-8619.6% margin

Net Income

$1M2341.2% margin

EPS (Diluted)

$1.04

QoQ Revenue Growth

-30.1%

Cash Flow

Operating Cash Flow

$0

Free Cash Flow

$0

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$23M

Total Liabilities

$20M

Stockholders' Equity

$3M

Cash & Equivalents

$12M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$51,000	$0	—
Gross Profit	$51,000	$0	—
Operating Income	-$4M	-$7M	+32.6%
Net Income	$1M	-$6M	+119.1%